Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva

ilustraciones, diagramas

Autores:: Pineda Arango, Harold Steven

Tipo de recurso:: Doctoral thesis

Fecha de publicación:: 2023

Institución:: Universidad Nacional de Colombia

Repositorio:: Universidad Nacional de Colombia

Idioma:: spa

id	UNACIONAL2_272e4c191bb4bfad7b90c138b29d884c
oai_identifier_str	oai:repositorio.unal.edu.co:unal/86630
network_acronym_str	UNACIONAL2
network_name_str	Universidad Nacional de Colombia
repository_id_str
dc.title.spa.fl_str_mv	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
dc.title.translated.eng.fl_str_mv	Evaluation of 24-month overall survival in adult patients with burkitt lymphoma: retrospective cohort
title	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
spellingShingle	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva 610 - Medicina y salud::616 - Enfermedades 610 - Medicina y salud::614 - Medicina Forense; incidencia de lesiones, heridas, enfermedades; medicina preventiva pública Lymphatic Vessel Tumors Lymphoma, B-Cell Linfoma de Burkitt Linfoma no Hodgkin Tumores de Vasos Linfáticos Linfoma de Células B Burkitt Lymphoma Lymphoma, Non-Hodgkin Adulto Pronostico Supervivencia Supervivencia sin progresión Adult Prognosis Survival Progression-free survival.
title_short	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
title_full	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
title_fullStr	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
title_full_unstemmed	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
title_sort	Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva
dc.creator.fl_str_mv	Pineda Arango, Harold Steven
dc.contributor.advisor.none.fl_str_mv	Combariza, Juan Felipe
dc.contributor.author.none.fl_str_mv	Pineda Arango, Harold Steven
dc.contributor.orcid.spa.fl_str_mv	Pineda Arango, Harold Steven [0009000979965246]
dc.subject.ddc.spa.fl_str_mv	610 - Medicina y salud::616 - Enfermedades 610 - Medicina y salud::614 - Medicina Forense; incidencia de lesiones, heridas, enfermedades; medicina preventiva pública
topic	610 - Medicina y salud::616 - Enfermedades 610 - Medicina y salud::614 - Medicina Forense; incidencia de lesiones, heridas, enfermedades; medicina preventiva pública Lymphatic Vessel Tumors Lymphoma, B-Cell Linfoma de Burkitt Linfoma no Hodgkin Tumores de Vasos Linfáticos Linfoma de Células B Burkitt Lymphoma Lymphoma, Non-Hodgkin Adulto Pronostico Supervivencia Supervivencia sin progresión Adult Prognosis Survival Progression-free survival.
dc.subject.armarc.eng.fl_str_mv	Lymphatic Vessel Tumors Lymphoma, B-Cell
dc.subject.decs.spa.fl_str_mv	Linfoma de Burkitt Linfoma no Hodgkin Tumores de Vasos Linfáticos Linfoma de Células B
dc.subject.decs.eng.fl_str_mv	Burkitt Lymphoma Lymphoma, Non-Hodgkin
dc.subject.proposal.spa.fl_str_mv	Adulto Pronostico Supervivencia Supervivencia sin progresión
dc.subject.proposal.eng.fl_str_mv	Adult Prognosis Survival Progression-free survival.
description	ilustraciones, diagramas
publishDate	2023
dc.date.issued.none.fl_str_mv	2023
dc.date.accessioned.none.fl_str_mv	2024-07-26T14:27:00Z
dc.date.available.none.fl_str_mv	2024-07-26T14:27:00Z
dc.type.spa.fl_str_mv	Trabajo de grado - Especialidad Médica
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/doctoralThesis
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/acceptedVersion
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_db06
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/TD
format	http://purl.org/coar/resource_type/c_db06
status_str	acceptedVersion
dc.identifier.uri.none.fl_str_mv	https://repositorio.unal.edu.co/handle/unal/86630
dc.identifier.instname.spa.fl_str_mv	Universidad Nacional de Colombia
dc.identifier.reponame.spa.fl_str_mv	Repositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourl.spa.fl_str_mv	https://repositorio.unal.edu.co/
url	https://repositorio.unal.edu.co/handle/unal/86630 https://repositorio.unal.edu.co/
identifier_str_mv	Universidad Nacional de Colombia Repositorio Institucional Universidad Nacional de Colombia
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Swerdlow SH CEHNJEPSSHTJVJ, World Health Organization. WHO Classification of tumours of Haematopoietic and Lymphoid Tissues. Vol. Revised 4th Edition. International Agency for Research on Cancer; 2017. 1–588 p. Roschewski M, Staudt LM, Wilson WH. Burkitt’s Lymphoma. Longo DL, editor. New England Journal of Medicine [Internet]. 2022 Sep 22;387(12):1111–22. Available from: http://www.nejm.org/doi/10.1056/NEJMra2025746 Ferry JA. Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. Oncologist. 2006 Apr 1;11(4):375–83. Burkitt. Nature. Nature. 1962;194:232–4. López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022 Dec 1;8(1). Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. Vol. 9, Medical sciences (Basel, Switzerland). NLM (Medline); 2021. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Nov 12;66(6):443–59. Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Konrad Mü Ller-Hermelink H, et al. LYMPHOID NEOPLASIA Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. 2012; Available from: http://ashpublications.org/blood/article-pdf/120/24/4795/1361357/zh805012004795.pdf Pavlovsky M, Cubero D, Gladys ;, Agreda-V ´ Asquez P, Enrico A, Mela-Osorio MJ, et al. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study [Internet]. 2022. Available from: https://ascopubs.org/go/authors/open-access Combariza JF, Lombana M, Torres AM, Castellanos AM, Arango M. General features and epidemiology of lymphoma in Colombia. A multicentric study. Ann Hematol. 2015 Jun 1;94(6):975–80. Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, et al. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Vol. 10, Insights into Imaging. Springer Verlag; 2019. Dunleavy K. ASSOCIATED CONTENT Approach to the Diagnosis and Treatment of Adult Burkitt’s Lymphoma. 2018; Available from: https://doi.org/10.1200/JOP. Magrath I. Epidemiology: Clues to the pathogenesis of Burkitt lymphoma. Vol. 156, British Journal of Haematology. 2012. p. 744–56. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer. 2010 Apr 1;126(7):1732–9. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. Journal of Clinical Oncology. 2005;23(19):4430–8. Slack GW, Gascoyne RD. MYC and Aggressive B-cell Lymphomas [Internet]. 2011. Available from: www.anatomicpathology.com Crombie J, Lacasce A. The treatment of Burkitt lymphoma in adults [Internet]. 2021. Available from: http://ashpublications.org/blood/article-pdf/137/6/743/1799971/bloodbld2019004099c.pdf Reutter K, Sandmann S, Rohde J, Müller S, Wöste M, Khanam T, et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia. 2021 Feb 1;35(2):639–43. Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021 Oct 7;81(19):4059-4075.e11. Durani U, Hogan WJ. Emergencies in haematology: tumour lysis syndrome. Vol. 188, British Journal of Haematology. Blackwell Publishing Ltd; 2020. p. 494–500. Bonnet C, Janssens A, Wu KL, Schroyens W, Van Hende V, Heimann P, et al. Practice Guidelines BHS Guidelines for the treatment of Burkitt’s lymphoma. Vol. 6, Belgian Journal of Hematology. 2015. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. Vol. 32, Journal of Clinical Oncology. American Society of Clinical Oncology; 2014. p. 3059–67. Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, et al. Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the norwegian radium hospital with the use of three successive regimens. Vol. 15, Annals of Oncology. Oxford University Press; 2004. p. 1072–8. Magrath L, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen. Vol. 14, Journal of Clinical Oncology. 1996. Stenning SP, Mead GM, Wright D, Sydes MR, Walewski J, Grigg A, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology. 2002;13(8):1264–74. Thomas DA, Cortes J, O’brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD Program in Burkitt’s-Type Adult Acute Lymphoblastic Leukemia. Vol. 17, Journal of Clinical Oncology. 1999. Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: Focus on CNS relapse. Blood Adv. 2021 Oct 26;5(20):3913–8. Hoelzer D, Walewski J, Viardot A, Hiddemann W, Spiekermann K, Serve H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood [Internet]. 2014;124(26):3870–9. Available from: http://ashpublications.org/blood/article-pdf/124/26/3870/1466166/3870.pdf Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, et al. AMC 048: Modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9;126(2):160–6. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, et al. Multicenter Study of Risk-Adapted Therapy with Dose-Adjusted EPOCH-R in Adults with Untreated Burkitt Lymphoma. Journal of Clinical Oncology. 2020 May 26;38(22):2519–29. Chamuleau M, Stenner F, Chitu D, Novak U, Minnema M, Visser O, et al. LB2370 R-CODOX-M/R-IVAC VERSUS DOSE-ADJUSTED(DA)-EPOCH-R IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK BURKITT LYMPHOMA; FIRST RESULTS OF A MULTI-CENTER RANDOMIZED HOVON/SAKK TRIAL [Internet]. Vol. 15, Luzerner Kantonsspital and SAKK. 2022. Available from: https://journals.lww.com/hemasphere/pages/default.aspx. López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022 Dec 1;8(1). Grillo-López AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, et al. Response criteria for NHL: Importance of “normal” lymph node size and correlations with response rates. Annals of Oncology. 2000;11(4):399–408. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Vol. 28, Annals of Oncology. Elsevier Ltd; 2017. p. 1436–47. Olszewski AJ, Lasse ;, Jakobsen H, Collins GP, Cwynarski K, Bachanova V, et al. Burkitt Lymphoma International Prognostic Index. J Clin Oncol [Internet]. 2021;39:1129–38. Available from: https://doi. Mukhtar F, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, et al. Survival predictors of Burkitt’s lymphoma in children, adults and elderly in the United States during 2000–2013. Int J Cancer. 2017 Apr 1;140(7):1494–502. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers [Internet]. Vol. 137. 2021. Available from: http://ashpublications.org/blood/article-pdf/137/3/374/1797623/bloodbld2020006926.pdf Yang X, Huang Q, Li A, Chen Y, Xu W, Li J, et al. A long-term retrospective study on sporadic Burkitt lymphoma in chinese population. Medicine. 2020 Jan 3;99(5):e18438. Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol. 2018 Feb 1;97(2):255–66. Silva WF da, Garibaldi PMM, Rosa LI da, Bellesso M, Clé DV, Delamain MT, et al. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates – A multicenter cohort study. Leuk Res. 2020 Feb 1;89. Fondo Colombiano de enfermedades de alto costo. Situación del Cancer en la Población Adulta atendida en el SGSSS de Colombia 2021. Bogotá D.C.; 2022. 1–284 p. Cairo MS, Bishop M. Tumour lysis syndrome: New therapeutic strategies and classification. Vol. 127, British Journal of Haematology. 2004. p. 3–11. Ministerio de salud. Resolución número 8430 de 1993, por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. 1993. Declaración de HELSINKI de la AMM.
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv	Atribución-NoComercial 4.0 Internacional
dc.rights.uri.spa.fl_str_mv	http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.extent.spa.fl_str_mv	44 páginas
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.coverage.temporal.none.fl_str_mv	2017-2021
dc.coverage.city.none.fl_str_mv	Bogotá
dc.coverage.country.none.fl_str_mv	Colombia
dc.publisher.spa.fl_str_mv	Universidad Nacional de Colombia
dc.publisher.program.spa.fl_str_mv	Bogotá - Medicina - Especialidad en Hematología
dc.publisher.faculty.spa.fl_str_mv	Facultad de Medicina
dc.publisher.place.spa.fl_str_mv	Bogotá, Colombia
dc.publisher.branch.spa.fl_str_mv	Universidad Nacional de Colombia - Sede Bogotá
institution	Universidad Nacional de Colombia
bitstream.url.fl_str_mv	https://repositorio.unal.edu.co/bitstream/unal/86630/1/license.txt https://repositorio.unal.edu.co/bitstream/unal/86630/2/1110448335.2024.pdf https://repositorio.unal.edu.co/bitstream/unal/86630/3/1110448335.2024.pdf.jpg
bitstream.checksum.fl_str_mv	eb34b1cf90b7e1103fc9dfd26be24b4a 8db54d9ee2542102d2e8daf63a5b6ceb bc949b29ff17558e1bf83b71e0b236a7
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad Nacional de Colombia
repository.mail.fl_str_mv	repositorio_nal@unal.edu.co
_version_	1814090243457941504
spelling	Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Combariza, Juan Felipe2232e92170580a6ecf5515a5dd7a5be3Pineda Arango, Harold Stevenbf689891144fa8af91b4a12021a012e2Pineda Arango, Harold Steven [0009000979965246]2017-2021BogotáColombia2024-07-26T14:27:00Z2024-07-26T14:27:00Z2023https://repositorio.unal.edu.co/handle/unal/86630Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, diagramasEl linfoma de Burkitt representa aproximadamente entre el 1 al 2% de los linfomas no Hodgkin en adultos según datos de Estados Unidos, sin embargo, su frecuencia en Latinoamérica parece ser ligeramente mayor encontrándose en diferentes series que representa alrededor del 3% de los linfomas no Hodgkin. En Colombia un estudio de cohorte retrospectiva encontró que representa un 7% de los linfomas no Hodgkin. El linfoma de Burkitt es muy sensible al tratamiento, siendo un tumor altamente curable con supervivencia libre de evento a 3 años del 75% y tasas de supervivencia global del 83%. En un estudio retrospectivo realizado en Estados Unidos se demostró que los esquemas de tratamiento más comúnmente usados en 30 centros fueron hyper-CVAD, R-EPOCH y CODOX-M/IVAC, sin diferencias en cuanto a los desenlaces. En Brasil, Wellington F. da Silva y colaboradores, realizaron un estudio retrospectivo multicéntrico, de pacientes con linfoma de Burkitt asociado a VIH, los esquemas de tratamiento usados con mayor frecuencia fueron Hyper CVAD en el 53 % de los pacientes y CODOX-M/IVAC en el 18%, en el análisis univariado, no hubo diferencias en cuanto a tasa de respuesta completa o supervivencia global con respecto a la edad, carga viral, CD4, o tipo de tratamiento empleado. Con respecto a Colombia, no se encontraron estudios específicos sobre Linfoma de Burkitt en población adulta (Texto tomado de la fuente).Burkitt lymphoma represents approximately 1 to 2% of non-Hodgkin lymphomas in adults according to data from the United States; however, its frequency in Latin America seems to be slightly higher, being found in different series to represent around 3% of cases. non-Hodgkin lymphomas. In Colombia, a retrospective cohort study found that it represents 7% of non-Hodgkin lymphomas. Burkitt lymphoma is very sensitive to treatment, being a highly curable tumor with 3-year event-free survival of 75% and overall survival rates of 83%. A retrospective study conducted in the United States showed that the most commonly used treatment regimens in 30 centers were hyper-CVAD, R-EPOCH, and CODOX-M/IVAC, with no differences in outcomes. In Brazil, Wellington F. da Silva et al. conducted a multicenter retrospective study of patients with HIV-associated Burkitt's lymphoma. The most frequently used treatment regimens were Hyper CVAD in 53% of the patients and CODOX-M/ VIA in 18%, in the univariate analysis, there were no differences in terms of complete response rate or overall survival with respect to age, viral load, CD4, or type of treatment used. With respect to Colombia, no specific studies on Burkitt's Lymphoma in the adult population were found.Especialidades MédicasEspecialista en HematologíaEstudio observacional de supervivencia en una cohorte retrospectiva, de pacientes adultos con diagnóstico de novo confirmado de linfoma de Burkitt, atendidos en la Clínica Universitaria Colombia entre el 1° de enero 2017 y el 31 de diciembre 2021. Se describieron las características clínicas y demográficas, los esquemas de tratamiento utilizados en primera línea y la asociación entre diferentes esquemas de tratamiento y los desenlaces de supervivencia global y supervivencia libre de recaída.44 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Especialidad en HematologíaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::616 - Enfermedades610 - Medicina y salud::614 - Medicina Forense; incidencia de lesiones, heridas, enfermedades; medicina preventiva públicaLymphatic Vessel TumorsLymphoma, B-CellLinfoma de BurkittLinfoma no HodgkinTumores de Vasos LinfáticosLinfoma de Células BBurkitt LymphomaLymphoma, Non-HodgkinAdultoPronosticoSupervivenciaSupervivencia sin progresiónAdultPrognosisSurvivalProgression-free survival.Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectivaEvaluation of 24-month overall survival in adult patients with burkitt lymphoma: retrospective cohortTrabajo de grado - Especialidad Médicainfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_db06Texthttp://purl.org/redcol/resource_type/TDSwerdlow SH CEHNJEPSSHTJVJ, World Health Organization. WHO Classification of tumours of Haematopoietic and Lymphoid Tissues. Vol. Revised 4th Edition. International Agency for Research on Cancer; 2017. 1–588 p.Roschewski M, Staudt LM, Wilson WH. Burkitt’s Lymphoma. Longo DL, editor. New England Journal of Medicine [Internet]. 2022 Sep 22;387(12):1111–22. Available from: http://www.nejm.org/doi/10.1056/NEJMra2025746Ferry JA. Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. Oncologist. 2006 Apr 1;11(4):375–83.Burkitt. Nature. Nature. 1962;194:232–4.López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022 Dec 1;8(1).Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. Vol. 9, Medical sciences (Basel, Switzerland). NLM (Medline); 2021.Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Nov 12;66(6):443–59.Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Konrad Mü Ller-Hermelink H, et al. LYMPHOID NEOPLASIA Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. 2012; Available from: http://ashpublications.org/blood/article-pdf/120/24/4795/1361357/zh805012004795.pdfPavlovsky M, Cubero D, Gladys ;, Agreda-V ´ Asquez P, Enrico A, Mela-Osorio MJ, et al. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study [Internet]. 2022. Available from: https://ascopubs.org/go/authors/open-accessCombariza JF, Lombana M, Torres AM, Castellanos AM, Arango M. General features and epidemiology of lymphoma in Colombia. A multicentric study. Ann Hematol. 2015 Jun 1;94(6):975–80.Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, et al. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Vol. 10, Insights into Imaging. Springer Verlag; 2019.Dunleavy K. ASSOCIATED CONTENT Approach to the Diagnosis and Treatment of Adult Burkitt’s Lymphoma. 2018; Available from: https://doi.org/10.1200/JOP.Magrath I. Epidemiology: Clues to the pathogenesis of Burkitt lymphoma. Vol. 156, British Journal of Haematology. 2012. p. 744–56.Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer. 2010 Apr 1;126(7):1732–9.Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. Journal of Clinical Oncology. 2005;23(19):4430–8.Slack GW, Gascoyne RD. MYC and Aggressive B-cell Lymphomas [Internet]. 2011. Available from: www.anatomicpathology.comCrombie J, Lacasce A. The treatment of Burkitt lymphoma in adults [Internet]. 2021. Available from: http://ashpublications.org/blood/article-pdf/137/6/743/1799971/bloodbld2019004099c.pdfReutter K, Sandmann S, Rohde J, Müller S, Wöste M, Khanam T, et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia. 2021 Feb 1;35(2):639–43.Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021 Oct 7;81(19):4059-4075.e11.Durani U, Hogan WJ. Emergencies in haematology: tumour lysis syndrome. Vol. 188, British Journal of Haematology. Blackwell Publishing Ltd; 2020. p. 494–500.Bonnet C, Janssens A, Wu KL, Schroyens W, Van Hende V, Heimann P, et al. Practice Guidelines BHS Guidelines for the treatment of Burkitt’s lymphoma. Vol. 6, Belgian Journal of Hematology. 2015.Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. Vol. 32, Journal of Clinical Oncology. American Society of Clinical Oncology; 2014. p. 3059–67.Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, et al. Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the norwegian radium hospital with the use of three successive regimens. Vol. 15, Annals of Oncology. Oxford University Press; 2004. p. 1072–8.Magrath L, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen. Vol. 14, Journal of Clinical Oncology. 1996.Stenning SP, Mead GM, Wright D, Sydes MR, Walewski J, Grigg A, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology. 2002;13(8):1264–74.Thomas DA, Cortes J, O’brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD Program in Burkitt’s-Type Adult Acute Lymphoblastic Leukemia. Vol. 17, Journal of Clinical Oncology. 1999.Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: Focus on CNS relapse. Blood Adv. 2021 Oct 26;5(20):3913–8.Hoelzer D, Walewski J, Viardot A, Hiddemann W, Spiekermann K, Serve H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood [Internet]. 2014;124(26):3870–9. Available from: http://ashpublications.org/blood/article-pdf/124/26/3870/1466166/3870.pdfNoy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, et al. AMC 048: Modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9;126(2):160–6.Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, et al. Multicenter Study of Risk-Adapted Therapy with Dose-Adjusted EPOCH-R in Adults with Untreated Burkitt Lymphoma. Journal of Clinical Oncology. 2020 May 26;38(22):2519–29.Chamuleau M, Stenner F, Chitu D, Novak U, Minnema M, Visser O, et al. LB2370 R-CODOX-M/R-IVAC VERSUS DOSE-ADJUSTED(DA)-EPOCH-R IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK BURKITT LYMPHOMA; FIRST RESULTS OF A MULTI-CENTER RANDOMIZED HOVON/SAKK TRIAL [Internet]. Vol. 15, Luzerner Kantonsspital and SAKK. 2022. Available from: https://journals.lww.com/hemasphere/pages/default.aspx.López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, et al. Burkitt lymphoma. Nat Rev Dis Primers. 2022 Dec 1;8(1).Grillo-López AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, et al. Response criteria for NHL: Importance of “normal” lymph node size and correlations with response rates. Annals of Oncology. 2000;11(4):399–408.Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Vol. 28, Annals of Oncology. Elsevier Ltd; 2017. p. 1436–47.Olszewski AJ, Lasse ;, Jakobsen H, Collins GP, Cwynarski K, Bachanova V, et al. Burkitt Lymphoma International Prognostic Index. J Clin Oncol [Internet]. 2021;39:1129–38. Available from: https://doi.Mukhtar F, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, et al. Survival predictors of Burkitt’s lymphoma in children, adults and elderly in the United States during 2000–2013. Int J Cancer. 2017 Apr 1;140(7):1494–502.Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers [Internet]. Vol. 137. 2021. Available from: http://ashpublications.org/blood/article-pdf/137/3/374/1797623/bloodbld2020006926.pdfYang X, Huang Q, Li A, Chen Y, Xu W, Li J, et al. A long-term retrospective study on sporadic Burkitt lymphoma in chinese population. Medicine. 2020 Jan 3;99(5):e18438.Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol. 2018 Feb 1;97(2):255–66.Silva WF da, Garibaldi PMM, Rosa LI da, Bellesso M, Clé DV, Delamain MT, et al. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates – A multicenter cohort study. Leuk Res. 2020 Feb 1;89.Fondo Colombiano de enfermedades de alto costo. Situación del Cancer en la Población Adulta atendida en el SGSSS de Colombia 2021. Bogotá D.C.; 2022. 1–284 p.Cairo MS, Bishop M. Tumour lysis syndrome: New therapeutic strategies and classification. Vol. 127, British Journal of Haematology. 2004. p. 3–11.Ministerio de salud. Resolución número 8430 de 1993, por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. 1993.Declaración de HELSINKI de la AMM.EstudiantesInvestigadoresMaestrosLICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/86630/1/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD51ORIGINAL1110448335.2024.pdf1110448335.2024.pdfTesis en Especialidad en Hematologíaapplication/pdf977956https://repositorio.unal.edu.co/bitstream/unal/86630/2/1110448335.2024.pdf8db54d9ee2542102d2e8daf63a5b6cebMD52THUMBNAIL1110448335.2024.pdf.jpg1110448335.2024.pdf.jpgGenerated Thumbnailimage/jpeg3993https://repositorio.unal.edu.co/bitstream/unal/86630/3/1110448335.2024.pdf.jpgbc949b29ff17558e1bf83b71e0b236a7MD53unal/86630oai:repositorio.unal.edu.co:unal/866302024-07-26 23:39:01.738Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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

Evaluación de la supervivencia global a 24 meses en pacientes adultos con linfoma de burkitt: cohorte retrospectiva

Publicaciones similares